Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
16
11
2022
accepted:
26
01
2023
revised:
24
01
2023
pmc-release:
10
02
2024
medline:
8
11
2023
pubmed:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
Longitudinal models of biomarkers such as tumour size dynamics capture treatment efficacy and predict treatment outcome (overall survival) of a variety of anticancer therapies, including chemotherapies, targeted therapies, immunotherapies and their combinations. These pharmacological endpoints like tumour dynamic (tumour growth inhibition) metrics have been proposed as alternative endpoints to complement the classical RECIST endpoints (objective response rate, progression-free survival) to support early decisions both at the study level in drug development as well as at the patients level in personalised therapy with checkpoint inhibitors. This perspective paper presents recent developments and future directions to enable wider and robust use of model-based decision frameworks based on pharmacological endpoints.
Identifiants
pubmed: 36765177
doi: 10.1038/s41416-023-02190-5
pii: 10.1038/s41416-023-02190-5
pmc: PMC10628227
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383-1388Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Clin Cancer Res. 2023 Mar 14;29(6):1047-1055
pubmed: 36595566
Clin Cancer Res. 2019 Sep 1;25(17):5342-5350
pubmed: 30936122
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007968
J Clin Oncol. 2009 Sep 1;27(25):4103-8
pubmed: 19636014
N Engl J Med. 2021 Oct 14;385(16):1445-1447
pubmed: 34623789
Stat Methods Med Res. 2016 Dec;25(6):2972-2991
pubmed: 24847900
Clin Cancer Res. 2020 Sep 15;26(18):4892-4900
pubmed: 32527941
CPT Pharmacometrics Syst Pharmacol. 2014 May 07;3:e113
pubmed: 24806032
JAMA Oncol. 2022 Dec 1;8(12):1733-1735
pubmed: 36264552
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
JAMA Netw Open. 2019 Sep 4;2(9):e1911750
pubmed: 31539075
Clin Cancer Res. 2018 Jul 15;24(14):3292-3298
pubmed: 29685883
Lancet Oncol. 2017 Jan;18(1):143-154
pubmed: 27979599
ESMO Open. 2022 Feb;7(1):100346
pubmed: 34954496
Clin Cancer Res. 2019 May 15;25(10):3035-3045
pubmed: 30745298
Nat Rev Cancer. 2006 May;6(5):409-14
pubmed: 16633367
CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1171-1182
pubmed: 34270868
Br J Cancer. 2022 Jul;127(2):173-184
pubmed: 35273384
Clin Transl Sci. 2022 Aug;15(8):1916-1925
pubmed: 35775126
Clin Pharmacol Ther. 2021 Nov;110(5):1172-1175
pubmed: 33991429
Br J Clin Pharmacol. 2022 Feb;88(4):1452-1463
pubmed: 34993985
Mol Cancer. 2022 Mar 18;21(1):79
pubmed: 35303879
Clin Pharmacol Ther. 2023 Apr;113(4):851-858
pubmed: 36606486
Cancer Res. 2020 Feb 1;80(3):591-601
pubmed: 31676575
Clin Cancer Res. 2020 Dec 15;26(24):6464-6474
pubmed: 32988968
J Clin Oncol. 2005 Feb 1;23(4):816-25
pubmed: 15681526
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1604-1613
pubmed: 36194478
JCO Precis Oncol. 2021 Nov;5:827-838
pubmed: 34994614
Clin Pharmacol Ther. 1997 Mar;61(3):275-91
pubmed: 9084453
Clin Pharmacol Ther. 2014 Apr;95(4):386-93
pubmed: 24419563
Nat Cancer. 2020 Sep;1(9):873-881
pubmed: 35121950
Clin Cancer Res. 2020 Apr 15;26(8):1787-1795
pubmed: 31871299
Eur J Cancer. 2021 Jul;151:211-220
pubmed: 34022698
Biom J. 2020 May;62(3):550-567
pubmed: 31310368
J Clin Oncol. 2013 Jun 10;31(17):2110-4
pubmed: 23650411
Pharmacol Res Perspect. 2021 Apr;9(2):e00757
pubmed: 33745217
CPT Pharmacometrics Syst Pharmacol. 2021 Jan;10(1):67-74
pubmed: 33319498
Pharm Res. 2022 Aug;39(8):1669-1680
pubmed: 35552984
Sci Rep. 2022 Mar 10;12(1):4206
pubmed: 35273301
Clin Cancer Res. 2019 Sep 1;25(17):5182-5184
pubmed: 31248883
JCO Precis Oncol. 2023 Feb;7:e2200368
pubmed: 36848611
JCO Precis Oncol. 2021 Nov;5:1540-1553
pubmed: 34994642
CPT Pharmacometrics Syst Pharmacol. 2021 Jan;10(1):59-66
pubmed: 33280255
CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):711-9
pubmed: 26904385
Clin Cancer Res. 2018 May 15;24(10):2268-2275
pubmed: 29326281